Skip to Main Content

Good morning, everyone, and how are you today? We are hobbling along, thank you, due to a nasty summer something. To cope, we are shifting gears and reaching for cups of stimulation that consist of tea leaves and honey. If nothing else, this is a nice image. We hope you are doing better. Toward that end, here are some tidbits. Have a smashing day and do keep us in mind when something interesting pops up …

A year-long survey of 50,000 drug samples made in India found they were safe and effective, the Economic Times writes, citing health ministry data. The survey, which used federal- and state-accredited laboratories in India, found a substandard rate of 3.5 percent, which was lower than the 4 percent to 5 percent rate found in the previous five-year period. The survey was conducted in response to rising concerns over the safety of medicines made in India.


Medivation chief executive David Hung could come out one of the big winners from the $14 billion buyout bid from Pfizer, while Sanofi, of course, is the big loser, the San Francisco Business Times writes. Hung could get change-of-control payouts worth upwards of $150 million. And BioMarin Pharmaceutical may get further royalties and milestones associated with a breast cancer drug sold last year to Medivation.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

  • I take Revlimid and would like to buy Natco’s Lenalid but am unable to do so mostly because of a deal made by Celgene to prevent its sale in the US Do you know of any way to obtain it??

Comments are closed.